Lilly Gets Limited European Backing for

礼来公司的阿尔茨海默病药物获得欧洲有限支持

By Sonja Wind and Ashleigh Furlong

作者:Sonja Wind 和 Ashleigh Furlong

July 25, 2025 at 6:55 PM GMT+8 Updated on July 25, 2025 at 7:36 PM GMT+8

2025年7月25日下午6:55 GMT+8 更新于 2025年7月25日下午7:36 GMT+8

Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer's disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in the region to slow the most common cause of dementia in the elderly.

⋯ 继续阅读请登录会员 ⋯